CREATE Medicines, Inc. (formerly Myeloid Therapeutics), a clinical-stage biotech pioneering in vivo multi-immune programming, today announced that clinical results from its Phase 1 MYE Symphony trial ...

INDICATION AUCATZYL ® is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory B-cell precursor acute ...

From streaming video and syncing data to connecting applications, the cloud plays an increasingly pivotal role in helping ...

NEW YORK, NY / ACCESS Newswire / November 7, 2025 / New to The Street, one of America’s leading business television and multi-platform media brands, today announced a comprehensive media partnership ...

Continuing our video series on UPMC Health Plan’s “Better Food, Better Health” pilot, faced with significant challenges, the team at UPMC Community HealthChoice, MANNA, and ...

One analysis showed participant costs were substantially lower – 8% below an employer client's general adult population and ...

These follow-up data from the ongoing CARLYSLE clinical trial support progressing obe-cel into ... Using a broad suite of proprietary and modular T cell programming technologies, Autolus is ...

Autolus Therapeutics plc (NASDAQ: AUTL) is one of the best stocks under $5 with highest upside potential. Autolus ...

Research into treatment for Valley fever, a fungal disease, continues, as does work on a vaccine to prevent it.

Inspire Medical Systems, Inc. ( INSP) UBS Global Healthcare Conference 2025 November 10, 2025 11:45 AM EST ...

A growing number of senior living providers are expanding Program of All-Inclusive Care for the Elderly (PACE) services to ...

Johnson & Johnson MedTech said the second round of the challenge opens this month. It plans to invite all first-round ...